Cargando…

Predicting new indications of compounds with a network pharmacology approach: Liuwei Dihuang Wan as a case study

With the ever increasing cost and time required for drug development, new strategies for drug development are highly demanded, whereas repurposing old drugs has attracted much attention in drug discovery. In this paper, we introduce a new network pharmacology approach, namely PINA, to predict potent...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yin-Ying, Bai, Hong, Zhang, Run-Zhi, Yan, Hong, Ning, Kang, Zhao, Xing-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706847/
https://www.ncbi.nlm.nih.gov/pubmed/29212201
http://dx.doi.org/10.18632/oncotarget.21398
_version_ 1783282298700955648
author Wang, Yin-Ying
Bai, Hong
Zhang, Run-Zhi
Yan, Hong
Ning, Kang
Zhao, Xing-Ming
author_facet Wang, Yin-Ying
Bai, Hong
Zhang, Run-Zhi
Yan, Hong
Ning, Kang
Zhao, Xing-Ming
author_sort Wang, Yin-Ying
collection PubMed
description With the ever increasing cost and time required for drug development, new strategies for drug development are highly demanded, whereas repurposing old drugs has attracted much attention in drug discovery. In this paper, we introduce a new network pharmacology approach, namely PINA, to predict potential novel indications of old drugs based on the molecular networks affected by drugs and associated with diseases. Benchmark results on FDA approved drugs have shown the superiority of PINA over traditional computational approaches in identifying new indications of old drugs. We further extend PINA to predict the novel indications of Traditional Chinese Medicines (TCMs) with Liuwei Dihuang Wan (LDW) as a case study. The predicted indications, including immune system disorders and tumor, are validated by expert knowledge and evidences from literature, demonstrating the effectiveness of our proposed computational approach.
format Online
Article
Text
id pubmed-5706847
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-57068472017-12-05 Predicting new indications of compounds with a network pharmacology approach: Liuwei Dihuang Wan as a case study Wang, Yin-Ying Bai, Hong Zhang, Run-Zhi Yan, Hong Ning, Kang Zhao, Xing-Ming Oncotarget Research Paper With the ever increasing cost and time required for drug development, new strategies for drug development are highly demanded, whereas repurposing old drugs has attracted much attention in drug discovery. In this paper, we introduce a new network pharmacology approach, namely PINA, to predict potential novel indications of old drugs based on the molecular networks affected by drugs and associated with diseases. Benchmark results on FDA approved drugs have shown the superiority of PINA over traditional computational approaches in identifying new indications of old drugs. We further extend PINA to predict the novel indications of Traditional Chinese Medicines (TCMs) with Liuwei Dihuang Wan (LDW) as a case study. The predicted indications, including immune system disorders and tumor, are validated by expert knowledge and evidences from literature, demonstrating the effectiveness of our proposed computational approach. Impact Journals LLC 2017-09-30 /pmc/articles/PMC5706847/ /pubmed/29212201 http://dx.doi.org/10.18632/oncotarget.21398 Text en Copyright: © 2017 Wang et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Wang, Yin-Ying
Bai, Hong
Zhang, Run-Zhi
Yan, Hong
Ning, Kang
Zhao, Xing-Ming
Predicting new indications of compounds with a network pharmacology approach: Liuwei Dihuang Wan as a case study
title Predicting new indications of compounds with a network pharmacology approach: Liuwei Dihuang Wan as a case study
title_full Predicting new indications of compounds with a network pharmacology approach: Liuwei Dihuang Wan as a case study
title_fullStr Predicting new indications of compounds with a network pharmacology approach: Liuwei Dihuang Wan as a case study
title_full_unstemmed Predicting new indications of compounds with a network pharmacology approach: Liuwei Dihuang Wan as a case study
title_short Predicting new indications of compounds with a network pharmacology approach: Liuwei Dihuang Wan as a case study
title_sort predicting new indications of compounds with a network pharmacology approach: liuwei dihuang wan as a case study
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706847/
https://www.ncbi.nlm.nih.gov/pubmed/29212201
http://dx.doi.org/10.18632/oncotarget.21398
work_keys_str_mv AT wangyinying predictingnewindicationsofcompoundswithanetworkpharmacologyapproachliuweidihuangwanasacasestudy
AT baihong predictingnewindicationsofcompoundswithanetworkpharmacologyapproachliuweidihuangwanasacasestudy
AT zhangrunzhi predictingnewindicationsofcompoundswithanetworkpharmacologyapproachliuweidihuangwanasacasestudy
AT yanhong predictingnewindicationsofcompoundswithanetworkpharmacologyapproachliuweidihuangwanasacasestudy
AT ningkang predictingnewindicationsofcompoundswithanetworkpharmacologyapproachliuweidihuangwanasacasestudy
AT zhaoxingming predictingnewindicationsofcompoundswithanetworkpharmacologyapproachliuweidihuangwanasacasestudy